Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-09
2011-12-27
Hui, San-Ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S537000
Reexamination Certificate
active
08084488
ABSTRACT:
Novel forms of atorvastatin magnesium salt designated Form A, Form B, Form C, Form D, Form E, and Form F, pharmaceutical compositions containing such compounds, methods for their preparation and methods utilizing the compounds for treatment of hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease are described.
REFERENCES:
patent: 4681893 (1987-07-01), Roth
patent: 5003080 (1991-03-01), Butler et al.
patent: 5097045 (1992-03-01), Butler et al.
patent: 5103024 (1992-04-01), Millar et al.
patent: 5124482 (1992-06-01), Butler et al.
patent: 5149837 (1992-09-01), Butler et al.
patent: 5155251 (1992-10-01), Butler et al.
patent: 5216174 (1993-06-01), Butler et al.
patent: 5245047 (1993-09-01), Butler et al.
patent: 5248793 (1993-09-01), Millar et al.
patent: 5273995 (1993-12-01), Roth
patent: 5280126 (1994-01-01), Butler et al.
patent: 5298627 (1994-03-01), Butler et al.
patent: 5342942 (1994-08-01), Jaen et al.
patent: 5397792 (1995-03-01), Butler et al.
patent: 5446054 (1995-08-01), Butler et al.
patent: 5470981 (1995-11-01), Butler et al.
patent: 5489690 (1996-02-01), Butler et al.
patent: 5489691 (1996-02-01), Butler et al.
patent: 5510488 (1996-04-01), Butler et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5969156 (1999-10-01), Briggs et al.
patent: 5998633 (1999-12-01), Jacks et al.
patent: 6087511 (2000-07-01), Lin et al.
patent: 6121461 (2000-09-01), McKenzie
patent: 6126971 (2000-10-01), Mills et al.
patent: 6433213 (2002-08-01), Bosch et al.
patent: 6476235 (2002-11-01), Butler et al.
patent: 6528660 (2003-03-01), Kumar et al.
patent: 6605636 (2003-08-01), Aronhime et al.
patent: 6605729 (2003-08-01), Byrn et al.
patent: 6867306 (2005-03-01), Srinath et al.
patent: 6891047 (2005-05-01), Pflaum
patent: 7030151 (2006-04-01), Kerc et al.
patent: 7074940 (2006-07-01), Sorsak
patent: 7342120 (2008-03-01), Aronhime et al.
patent: 7361772 (2008-04-01), Mathew et al.
patent: 2003/0175338 (2003-09-01), Singh et al.
patent: 2004/0063969 (2004-04-01), Greff et al.
patent: 2005/0209306 (2005-09-01), Jegorov et al.
patent: 2006/0122403 (2006-06-01), Suri et al.
patent: 2006/0205805 (2006-09-01), Van Der Schaaf et al.
patent: 1 336 405 (2002-02-01), None
patent: 1336405 (2003-08-01), None
patent: WO0136384 (2001-05-01), None
patent: WO02057228 (2002-07-01), None
patent: WO02083637 (2002-10-01), None
patent: WO02083638 (2002-10-01), None
patent: WO2006008091 (2006-01-01), None
patent: WO2006054308 (2006-05-01), None
patent: WO2006070248 (2006-07-01), None
patent: WO2006084474 (2006-08-01), None
patent: WO2006117761 (2006-11-01), None
patent: WO 2006117761 (2006-11-01), None
patent: WO 2007/132472 (2007-11-01), None
patent: WO2007132472 (2007-11-01), None
Hancock, B. C., et al., Comparisonof the mechanical properties of the crystalline and amorphous forms of a drug substance,International Journal of Pharmaceutics, vol. 241, pp. 73-85, (2002).
Hiestand, H. E. N., et al., Indices of Tableting Performance,Powder Technology, vol. 38, pp. 145-159, (1984).
Konno, T., Physical and Chemical Changes of Medicinals in Mixtures with Adsorbents in the Solid State. IV. Study on Reduced-Pressure Mixing for Practical Use of Amorphous Mixtures of Flufenamic Acid,Chem. Pharm. Bull., vol. 38, No. 7, pp. 2002-2007.
Notice of Opposition to a European Patent.
Comparison of the 13C Solid State NMR Spectra of Forms E and B4 of Atorvastatin Magnesium.
Protocol of Solubility Study.
13C solid state NMR spectrum of the form B4 of atorvastatin magnesium.
Description of manufacturing method for preparing atorvastatin magnesium.
13C solid state NMR spectrum of the pure atorvastatin magnesium.
13C solid state NMR spectrum of the crude atorvastatin magnesium.
Caira, M. R., et al.,Topics in Current Chemistry, vol. 198, pp. 163-208, (1998).
Statement of Claim.
Statement of Opposition (including these documents): Priority document for WO 2006/117761, Excerpt from British Pharmacopeia, 1993; Declaration of Dr. Ron Lawrence dated Feb. 4, 2011; Pharmaceutical Production—An Engineering Guide, Eds. B. Bennett and G. Cole, IChemE, 2003, pp. 85-96, Vogel's Textbook of Practical Organic Chemistry—Fifth Edition, Eds. B. S. Furnis et al., Pearson Prentice Hall, 1989, pp. 131-1333, Handbook of Pharmaceutical Salts—Properties, Selection and Use, Eds. P. H. Stahl and G. Wermuth, Verlay Helvetica Chimica Acta, 2002, pp. 67-74.
Leonard Jason A.
Miller Jonathan M.
Benson Gregg C.
Cruz Kathrien
Hui San-Ming
Pfizer Inc.
Tinney Francis J.
LandOfFree
Forms of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Forms of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Forms of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4266571